As a biomarker, SLC16A1-AS1 has been reported in hepatocellular carcinoma (HCC), cervical squamous cell carcinoma (CSCC), glioblastoma, bladder cancer, oral squamous cell carcinoma (OSCC), and non-small cell lung cancer (NSCLC). Here, SLC16A1 is linked to non-small cell lung carcinoma.